Company news
Tscan Therapeutics, Inc. (NASDAQ:TCRX) news
Every Tscan Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 30, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Hem...
June 22, 2026
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 3, 2026
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
April 27, 2026
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Appl...
February 26, 2026
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual ...
December 6, 2025
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
December 3, 2025
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 5, 2025
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-1...
November 3, 2025
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
September 17, 2025
TScan Therapeutics to Participate in Upcoming Investor Conferences
September 3, 2025
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 28, 2025
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 6, 2025
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
April 28, 2025
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
March 27, 2025
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 5, 2025
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 18, 2025
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
December 26, 2024
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
December 23, 2024
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hemat...
November 5, 2024
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
October 4, 2024
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
TScan Therapeutics Announces Updates to its Board of Directors
June 14, 2024
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for...
May 29, 2024
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
May 9, 2024
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
April 24, 2024
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 22, 2024
TScan Therapeutics Announces Closing of Upsized Public Offering
April 19, 2024
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
April 17, 2024
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
April 16, 2024
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
April 8, 2024
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 2, 2024
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 6, 2024
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CI...
February 26, 2024
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
February 6, 2024